Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
(4) - EconoTimes)
BERKELEY, Calif., March 01, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common stock to six new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.05 per share, the closing price of Dynavax’s common stock on March 1, 2018, the effective date of such grants. The stock options awarded vest over a three-year period, with one-third of the shares subject to such awards vesting on the first anniversary of the award’s vesting commencement date, and 1/36th of the shares subject to such awards vesting monthly thereafter, subject to each such employee’s continued employment with Dynavax on such vesting dates.
Dynavax is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, IR & Corporate Communications
510.665.7269
[email protected]
